Brevan Howard Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Brevan Howard Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.6K	Buy	+10,090	New	+$34.2K	﹤0.01%	2108
2025 Q4	–	Sell	-24,093	Closed	-$69.1K	–	2116
2025 Q3	$69.1K	Buy	+24,093	New	+$61.5K	﹤0.01%	1887
2024 Q1	–	Sell	-22,414	Closed	-$147K	–	1225
2023 Q4	$147K	Buy	+22,414	New	+$145K	﹤0.01%	917

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brevan Howard Capital Management's MRVI Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Maravai LifeSciences (MRVI) in Q1 2026: 10,090 shares worth $28.6K. The stake represents ﹤0.01% of the portfolio and ranks #2108 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in MRVI as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in MRVI in Q4 2023 and has held it in 3 quarters since. The position peaked at $147K in Q4 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Brevan Howard Capital Management held 10,090 shares of Maravai LifeSciences worth $28.6K as of Q1 2026.
Maravai LifeSciences was a new Brevan Howard Capital Management position in Q1 2026.
Maravai LifeSciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2108 holding.
Brevan Howard Capital Management first reported a position in Maravai LifeSciences in Q4 2023 and has held it in 3 quarters since.
Brevan Howard Capital Management's Maravai LifeSciences position peaked at $147K in Q4 2023.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.